Brad Klein

1.4k total citations
16 papers, 463 citations indexed

About

Brad Klein is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Physiology. According to data from OpenAlex, Brad Klein has authored 16 papers receiving a total of 463 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Psychiatry and Mental health, 7 papers in Pathology and Forensic Medicine and 5 papers in Physiology. Recurrent topics in Brad Klein's work include Migraine and Headache Studies (11 papers), Trigeminal Neuralgia and Treatments (5 papers) and Sympathectomy and Hyperhidrosis Treatments (4 papers). Brad Klein is often cited by papers focused on Migraine and Headache Studies (11 papers), Trigeminal Neuralgia and Treatments (5 papers) and Sympathectomy and Hyperhidrosis Treatments (4 papers). Brad Klein collaborates with scholars based in United States, Brazil and Italy. Brad Klein's co-authors include Neil A. Busis, Jessica Ailani, Paul G. Mathew, Rebecca Barmherzig, Steven D. Bender, Christina L. Szperka, David W. Dodick, Andrew Blumenfeld, Robert E. Shapiro and Avi Ashkenazi and has published in prestigious journals such as Neurology, Headache The Journal of Head and Face Pain and Cephalalgia.

In The Last Decade

Brad Klein

14 papers receiving 443 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brad Klein United States	8	273	170	131	105	94	16	463
Mamuka Djibuti Georgia	9	307 1.1×	133 0.8×	78 0.6×	52 0.5×	16 0.2×	10	394
K.A.S.L. Ferreira Brazil	8	50 0.2×	37 0.2×	154 1.2×	118 1.1×	77 0.8×	13	514
Aline Pereira da Rocha Brazil	11	58 0.2×	25 0.1×	60 0.5×	61 0.6×	45 0.5×	23	349
Javier Luis López Hidalgo Spain	14	389 1.4×	48 0.3×	98 0.7×	13 0.1×	21 0.2×	38	665
Sergio Núñez de Arenas‐Arroyo Spain	12	34 0.1×	48 0.3×	99 0.8×	54 0.5×	58 0.6×	37	426
Mai Luu Vietnam	10	54 0.2×	27 0.2×	206 1.6×	86 0.8×	37 0.4×	49	532
Álvaro Sierra Spain	8	124 0.5×	68 0.4×	36 0.3×	182 1.7×	10 0.1×	27	326
Basil Akpunonu United States	10	163 0.6×	77 0.5×	73 0.6×	32 0.3×	13 0.1×	23	383
M.I. Pedraza Spain	13	320 1.2×	234 1.4×	139 1.1×	216 2.1×	5 0.1×	30	540
Ellen Flanagan United States	11	38 0.1×	46 0.3×	69 0.5×	38 0.4×	84 0.9×	15	481

Countries citing papers authored by Brad Klein

Since Specialization

Citations

This map shows the geographic impact of Brad Klein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brad Klein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brad Klein more than expected).

Fields of papers citing papers by Brad Klein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brad Klein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brad Klein. The network helps show where Brad Klein may publish in the future.

Co-authorship network of co-authors of Brad Klein

This figure shows the co-authorship network connecting the top 25 collaborators of Brad Klein. A scholar is included among the top collaborators of Brad Klein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brad Klein. Brad Klein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Ailani, Jessica, Richard Lipton, Andrew Blumenfeld, et al.. (2024). Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM study. Headache The Journal of Head and Face Pain. 65(6). 1005–1014. 4 indexed citations

Schwedt, Todd J., Richard B. Lipton, Peter J. Goadsby, et al.. (2024). Characterizing Prodrome (Premonitory Phase) in Migraine. Neurology Clinical Practice. 15(1). e200359–e200359. 8 indexed citations

Ramanan, Vijay K., Melissa J. Armstrong, Parichita Choudhury, et al.. (2023). Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease. Neurology. 101(19). 842–852. 42 indexed citations

Schwedt, Todd J., Richard B. Lipton, Peter J. Goadsby, et al.. (2023). Characterizing Prodrome (Premonitory Phase) in Migraine: Results From the PRODROME Trial Screening Period (S41.009). Neurology. 100(17_supplement_2). 3 indexed citations

Klein, Brad, Rosa Miceli, Lawrence Severt, et al.. (2023). Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial. Cephalalgia. 43(1). 2205173306–2205173306. 17 indexed citations

Klein, Brad, Rosa Miceli, Lawrence Severt, et al.. (2022). Evaluation of the Long-Term Safety and Tolerability of Oral Atogepant 60 Mg Once Daily for Preventive Treatment of Migraine: A Phase 3, 40-Week, Multicenter Extension to the Advance Trial (P3-2.001). Neurology. 98(18_supplement).

Klein, Brad, et al.. (2022). P.020 Long-term safety and tolerability of atogepant 60mg once daily for preventive treatment of migraine: a phase 3, 40-week, multicenter extension to the advance trial. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 49(s1). S13–S13. 1 indexed citations

Jackson, Carlayne E., et al.. (2021). Futures Planning at the AAN. Neurology. 96(22). 1032–1040.

Ailani, Jessica, et al.. (2021). Safety and Tolerability of Ubrogepant Within Various Demographic and Clinical Characteristic Subgroups (1249). Neurology. 96(15_supplement). 1 indexed citations

10.

Szperka, Christina L., Jessica Ailani, Rebecca Barmherzig, et al.. (2020). Migraine Care in the Era of COVID‐19: Clinical Pearls and Plea to Insurers. Headache The Journal of Head and Face Pain. 60(5). 833–842. 69 indexed citations

11.

Klein, Brad & Neil A. Busis. (2020). COVID-19 is catalyzing the adoption of teleneurology. Neurology. 94(21). 903–904. 120 indexed citations

12.

Mathew, Paul G. & Brad Klein. (2019). Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second‐Generation Gepants, and Cardiovascular Risk. Headache The Journal of Head and Face Pain. 59(8). 1421–1426. 26 indexed citations

13.

Ney, John P., et al.. (2018). Association of neurologist care with headache expenditures: A population-based, longitudinal analysis. Cephalalgia. 38(12). 1876–1884. 3 indexed citations

14.

Mathew, Paul G., et al.. (2016). A retrospective analysis of triptan and dhe use for basilar and hemiplegic migraine. Headache The Journal of Head and Face Pain. 56(5). 841–848. 25 indexed citations

15.

Blumenfeld, Andrew, Avi Ashkenazi, Uri Napchan, et al.. (2013). Expert Consensus Recommendations for the Performance of Peripheral Nerve Blocks for Headaches – A Narrative Review. Headache The Journal of Head and Face Pain. 53(3). 437–446. 143 indexed citations

16.

Klein, Brad, et al.. (1980). Artrite reumatoide juvenil. 80(4). 447–452. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact